Thrombotic Microangiopathy in ABO-incompatible Kidney Transplant - Eculizumab to the Rescue

被引:0
作者
Khan, Mohammed Fahad [1 ]
Siddini, Vishwanath [1 ]
Mahesha, V. [1 ]
Ballal, Sudarshan [1 ]
机构
[1] Manipal Hosp, Manipal Inst Nephrol & Urol, Dept Nephrol, Bengaluru, Karnataka, India
关键词
ABO incompatible; eculizumab; thrombotic microangiopathy; ANTIBODY-MEDIATED REJECTION; PATIENT; HLA;
D O I
10.4103/ijot.ijot_8_23
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
A 51 year old gentleman diagnosed with end stage renal disease due to Autosomal dominant polycystic kidney disease underwent an ABO-incompatible transplant with his wife as the donor. He was given two doses of Rituximab 500mg prior to transplant and started on tacrolimus and mycophenolate mofetil fourteen days prior transplant. His baseline titres for Anti-A IgG were 1:32 and he underwent three sessions of Double filtration plasmapheresis, and pretransplant titres reduced to 1:1. Within 6 hours of the transplant surgery his urine output showed a drop and Renal angiogram showed patchy enhancement of the kidney in the interpolar region and lower pole with suspected acute kink in the arterial branch supplying the upper pole. He was re-explored in view of the kink, and an allograft biopsy was done and no kink was detected. Intraoperative renal artery doppler showed good blood flow with no evidence of thrombosis. The renal biopsy was reported to have 20-25% cortical necrosis with Vascular and Glomerular Thrombotic microangiopathy. Anti A titres were 1:16. He was subsequently treated with 7 sessions of plasmapheresis, 60 grams of IVIg and 2250mg of methylprednisolone. His urine output showed marginal improvement and was subsequently treated with two doses of 600mg Eculizumab given one week apart. Over the next few weeks his urine output improved to more than 3000ml per day and creatinine improved to 2.5mg/dl. This case highlights salvage of a hyperacute rejection with TMA with timely plasmapheresis and Eculizumab.
引用
收藏
页码:75 / 77
页数:3
相关论文
共 15 条
  • [1] Kidney transplantation across HLA and ABO antibody barriers
    Becker, Luis E.
    Suesal, Caner
    Morath, Christian
    [J]. CURRENT OPINION IN ORGAN TRANSPLANTATION, 2013, 18 (04) : 445 - 454
  • [2] Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation
    Biglarnia, Ali-Reza
    Nilsson, Bo
    Nilsson, Thomas
    von Zur-Muhlen, Bengt
    Wagner, Michael
    Berne, Christian
    Wanders, Alkwin
    Magnusson, Anders
    Tufveson, Gunnar
    [J]. TRANSPLANT INTERNATIONAL, 2011, 24 (08) : E61 - E66
  • [3] Chang Alexander T, 2009, Transplant Rev (Orlando), V23, P191, DOI 10.1016/j.trre.2009.06.002
  • [4] Establishing Hematopoietic Stem Cell Transplant Unit in Resource Limited Setting: A Critical Analysis of Indian Council of Medical Research 2017 Guidelines
    Das, Kunal
    Khanna, Tanvi
    Agrawal, Nitika
    [J]. JOURNAL OF TRANSPLANTATION, 2018, 2018
  • [5] Eculizumab in Transplant-Associated Thrombotic Microangiopathy
    Dhakal, Prajwal
    Giri, Smith
    Pathak, Ranjan
    Bhatt, Vijaya Raj
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2017, 23 (02) : 175 - 180
  • [6] Thrombotic Microangiopathy and Rejection in Blood Group Incompatible Renal Transplantation
    Etta, Praveen Kumar
    [J]. INDIAN JOURNAL OF TRANSPLANTATION, 2020, 14 (01) : 5 - 7
  • [7] The emerging role of complement inhibitors in transplantation
    Fremeaux-Bacchi, Veronique
    Legendre, Christophe M.
    [J]. KIDNEY INTERNATIONAL, 2015, 88 (05) : 967 - 973
  • [8] Use of Eculizumab in Transplant-Associated Thrombotic Microangiopathy in a Patient With Polycystic Kidney Disease Immediately Post-Kidney Transplant: A Case Report
    Godara, Amandeep
    Migliozzi, Daniel R.
    Pilichowska, Monika
    Goyal, Nitender
    Varga, Cindy
    Gordon, Craig E.
    [J]. KIDNEY MEDICINE, 2020, 2 (05) : 652 - 656
  • [9] Lanfranco L., 2017, Case Rep Transplant, V2017, P319
  • [10] Eculizumab and Splenectomy as Salvage Therapy for Severe Antibody-Mediated Rejection After HLA-Incompatible Kidney Transplantation
    Orandi, Babak J.
    Zachary, Andrea A.
    Dagher, Nabil N.
    Bagnasco, Serena M.
    Garonzik-Wang, Jacqueline M.
    Van Arendonk, Kyle J.
    Gupta, Natasha
    Lonze, Bonnie E.
    Alachkar, Nada
    Kraus, Edward S.
    Desai, Niraj M.
    Locke, Jayme E.
    Racusen, Lorraine C.
    Segev, Dorry L.
    Montgomery, Robert A.
    [J]. TRANSPLANTATION, 2014, 98 (08) : 857 - 863